Yin and colleagues recently demonstrated the significance of the high density and spatial proximity of CD8+ T cells to tumor cells, demonstrating their correlation with improved responses to nivolumab, whereas the close proximity of Tregs to tumor cells correlated with poorer responses (26). This evidence concerns the gene CD8A and neoplasm.